JDRF’s research goal is to discover, develop, and deliver advances that progressively remove the impact of T1D from people’s lives until we find a cure. JDRF is driving research across the entire scientific spectrum, from discovery in the laboratory to delivery of new technologies and treatments to people with T1D.
The full impact of JDRF’s research investment extends well beyond our direct funding. Now more than ever, we see the value in leveraging partnerships with academia, industry and clinicians to ensure that the most promising research opportunities are funded and accelerated. JDRF often provides early-stage funding to research projects, and the results of those projects often lead to follow-on participation from many other entities—both other not-for-profit funders and corporations.
Our investments are supporting the development of next-generation therapies like artificial pancreas technology, beta cell encapsulation, smart insulin that can turn on and off in response to blood sugar levels and, ultimately, methods for curing and preventing T1D.
- JDRF is the leading global organization funding T1D research with more than 100 U.S. locations and 6 international affiliates.
- Since inception, JDRF has contributed over $1.9B to T1D research and including $98M in 2014.
- JDRF is currently funding 45 human clinical trials of potential T1D therapies.
- Approximately 80% of JDRF expenditures directly support T1D research and research-related education